Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of$ 0.23. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.04%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.22 per share when it actually produced a loss of $0.24, delivering a surprise of -9.09%.Over the last four quarters, the co ...